Post-transplant Thrombotic Microangiopathy: Observational Study on Outcomes in Kidney Transplant Patients at Bologna Centre

What this Trial Is About

Researchers are studying post-transplant thrombotic microangiopathy (PT-TMA) in kidney transplant patients to understand how often it occurs and how it affects kidney transplant outcomes. This research involves both retrospective and prospective collection of patient data to support scientific knowledge and health protection. The study is conducted at a single center, the Bologna Kidney Transplant Centre, and focuses on patients diagnosed with PT-TMA starting from June 1, 2016, continuing for 10 years after study approval. This study does not involve drug treatments but systematically gathers clinical information from kidney transplant recipients diagnosed with PT-TMA. Patients enrolled prospectively will receive treatment based on clinical practice and physician judgment. The patient group includes various types of kidney transplants such as living donor, brain death cadaver donor, cardiac death cadaver donor, single, double, and combined kidney transplants. Participants will be monitored over time with follow-up assessments at 15 days, 1 month, 6 months, and every 6 months after transplantation to measure the incidence of PT-TMA and evaluate kidney graft outcomes. Data collected include clinical information relevant to PT-TMA diagnosis and transplant results. The study aims to provide valuable insights over a long-term period of up to 10 years after study approval.

Post-transplant Thrombotic Microangiopathy: Evaluation of Outcomes at the Bologna Kidney Transplant Centre